Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide fromShigella dysenteriaetype 1
- 27 April 1999
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (9) , 5194-5197
- https://doi.org/10.1073/pnas.96.9.5194
Abstract
Our development of vaccines to prevent shigellosis is based on the hypothesis that a critical (protective) level of serum IgG to the O-specific polysaccharide (O-SP) domain ofShigellalipopolysaccharide (LPS) confers immunity. The O-SP is a hapten and must be conjugated to a protein to induce serum antibodies. The O-SP ofShigella dysenteriaetype 1 (≈27 tetrasaccharide repeat units), prepared by acid hydrolysis of the LPS, was bound to human serum albumin (HSA) by multiple point attachment (O-SP-HSA): The molar ratio of HSA to O-SP was 1.0. Synthetic saccharides, composed of one or multiples of the O-SP tetrasaccharide, equipped with a spacer at their reducing end, were bound to HSA by a single point attachment: The average molar ratios of the saccharides to HSA ranged from 4 to 24. Serum IgG anti-LPS, elicited in mice by O-SP-HSA or synthetic tetra-, octa-, dodeca-, and hexadecasaccharide fragments, was measured by ELISA. Outbred 6-week-old female mice were injected s.c. three times at biweekly intervals with 2.5 μg of saccharide as a conjugate and were bled 7 days after the second and third injections. Excepting the tetramer, conjugates of the octamer, dodecamer and hexadecamer elicited IgG LPS antibodies after the second injection, a statistically significant rise (booster) after the third injection, and higher levels than those vaccinated with O-SP-HSA (P= 0.0001). The highest geometric mean levels of IgG anti-LPS were elicited by the hexadecamer with 9 chains or 9 moles of saccharide/HSA (15.5 ELISA units) followed by the octamer with 20 chains (11.1 ELISA units) and the dodecamer with 10 chains (9.52 ELISA units). Clinical evaluation of these synthetic saccharides bound to a medically useful carrier is planned.Keywords
This publication has 49 references indexed in Scilit:
- The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicityVaccine, 1997
- The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccinesJAMA, 1996
- A Convergent Synthesis of a Hexadecasaccharide Fragment of the O-Polysaccharide of Shigella dysenteriae Type 1Journal of the American Chemical Society, 1995
- Hypothesis for Vaccine Development: Protective Immunity to Enteric Diseases Caused by Nontyphoidal Salmonellae and Shigellae May Be Conferred by Serum IgG Antibodies to the O-Specific Polysaccharide of Their LipopolysaccharidesClinical Infectious Diseases, 1992
- Toxin Genotypes and Plasmid Profiles as Determinants of Systemic Sequelae in Escherichia coli O157:H7 InfectionsThe Journal of Infectious Diseases, 1989
- Serum Antibodies to Lipopolysaccharide and Natural Immunity to Shigellosis in an Israeli Military PopulationThe Journal of Infectious Diseases, 1988
- Risk factors for development of hemolytic uremic syndrome during shigellosisThe Journal of Pediatrics, 1987
- Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197.Journal of Clinical Investigation, 1985
- Haemolytic-uraemic syndrome complicating shigella dystentery in south Indian children.BMJ, 1978
- Somatic Antigens of Shigella. The Structure of the Specific Polysaccharide Chain of Shigella dysenteriae Type 5 LipopolysaccharideEuropean Journal of Biochemistry, 1977